Monetha Challenges PayPal – Ethereum blockchain based mobile payment processing company Monetha, is powered by smart contracts with

Monetha Challenges PayPal’s and Trustpilot’s Status Quo with the Ethereum Blockchain

Bitcoin Press Release: Blockchain startup Monetha offers a more efficient and safer crypto-payment gateway system through Ethereum-based payments, announces ICO date.

 Monetha Challenges PayPal – Ethereum blockchain based mobile payment processing company Monetha, is powered by smart contracts with

FOREX INVESTORS Monetha Challenges PayPal – Ethereum blockchain based mobile payment processing company Monetha, is powered by smart contracts with a decentralized trust and reputation system. Monetha’s service offers a faster, safer, and cheaper, decentralized payment gateway alternative to the current system employed by most of the today’s retailers and merchants. Monetha is best summed up as a combination of PayPal and Trustpilot, run on the Ethereum blockchain. The fintech company has announced its upcoming ICO campaign, which will commence on the 22nd of August 2017.

Monetha’s decentralized trust and reputation system (DTRS) uses smart contracts that integrate flawlessly with the payment processor. It is designed to build trust between buyers and sellers by recording vital information like product warranty and more regarding the transactions on the blockchain. An inbuilt algorithm analyzes the reputation of the users and assigns trust rating to each party. The trust rating is constantly adjusted based on the reviews, records on claims and disputes and more. By doing so, it solves the trust problem associated with transactions, especially when it comes to online purchases on domestic and international sites. It solves the lifelong trust problem between the parties, helping them avoid pitfalls like scams, charge-backs, and faulty goods, etc. Apart from e-commerce, Monetha’s decentralized trust and reputation system is also compatible with retail applications.

The co-founder and business lead at Monetha, Justas Pikelis said,




 FOREX INVESTORS

Monetha Challenges PayPal

 

 

“We are very excited to start the revolution of global commerce by bringing trust and efficiency for both the merchants and the clients.”

Users can purchase products from all over the world in any Ethereum-based cryptocurrency and Monetha will automatically convert their chosen cryptocurrency back into a fiat currency of their choice. The platform generates a QR code that can be scanned by cryptowallets for making payments, and once the transaction is initiated, the merchant will receive the funds in typically under a minute, and they have to pay no more than 1.5% as commission.

Monetha’s system is both easy, fast and cheap, compared to the current centralized alternatives. Monetha’s unique service guarantees all parties safety through the Ethereum blockchain and the ability for both parties to give each other ratings, to help improve their reputation.

Despite the presence of a range of payment gateways and processing service providers, merchants continue to face a lot of issues due to multiple steps (up to 15 steps at times) involved in the process, starting from setting up to settlements. Also, the transaction and services fees associated with traditional gateways are generally at the higher end. Merchants usually end up paying anywhere between 2% and 6% per transaction. Whereas, the Monetha service involves a single step and costs a fixed transaction fee of 1.5%.

Monetha also offers an added advantage in terms of processing time, which might vary with conventional payments solution providers. The waiting times for processing payments on standard gateways range from minutes to hours or even days. They also come with complex claim and chargeback procedures which could prove costly to the merchants. Meanwhile, payment processing on Ethereum blockchain is 10,000 times faster at 20% the price.

Monetha Co-Founder and Head of Technology Andrej Ruckij summing up what Monetha means to merchants said,

“With no centralized Authority, it’s literally like a merchant becoming his own bank.”

Monetha’s mission is to become a strong force in the global commerce, offering a reliable, transparent and decentralized payment gateway to all users worldwide.

Launching in January 2017 Monetha has a meticulously thought out roadmap leading to 2019 when its services aim to reach full maturity. Currently, in phase two, Monetha has already put together a capable team, finished strategizing and gone through comprehensive prototyping. The phase three in the company’s timeline involves the launch of its token sale, starting 22nd of August 2017, which they believe will be a significant step towards turning the minimum viable product into a finished product.

Monetha’s decentralized trust and reputation system takes every facet of traditional e-commerce and retail and improves on it. With their groundbreaking, unique service and a successful ICO Monetha has the potential to revolutionize the way payment systems function around the world.

Learn more about Monetha at – http://www.monetha.io
Access Monetha whitepaper at – http://www.monetha.io/static/media/Monetha_White_Paper.050930a4.pdf
Follow Monetha on Facebook – https://www.facebook.com/Monetha.io
Follow M



Top Pick of 2017, Shopify Stock Earns Its Rock Star Status

SHOP Stock: Shining Bright

BUZ INVESTORS Shopify Stock Earns  The first quarter is in the books, and this provides an opportunity to take a look at how my rock star top pick for 2017 has played out year-to-date. On December 27, 2016, I gave the honor of naming Shopify Inc (NYSE:SHOP) stock as my rock star top pick of 2017. At the time of that report, Shopify stock was trading at $43.64, and it is now trading at $69.23. In a matter of three months, SHOP stock has appreciated to the tune of 56.37%. This performance in the first quarter is quite astonishing, but rightfully so, this is my rock star top pick for 2017.

I generate my investment views using technical analysis. This method of investment analysis is based on the notion that historical price and volume data can be used to discern trends and forecast future prices. As a result, my analysis is heavily weighted by the price action and indicators that are generated on a company’s price chart. I have been refining my craft in this method of analysis for nearly two decades, and have become fairly proficient in generating an accurate view. It was this method of analysis that suggested that Shopify shares were due for an explosive run.



OTHER STORIES BUZ TRADERS FOLLOW

Shopify Stock Earns

The appreciation in price is especially impressive because the trend towards higher prices that began in February 2016 began to accelerate significantly. This significant acceleration in price is captured using a simple uptrend line. This trend is very steep. At this pace, Shopify shares will be challenging the $100.00 mark before year end.

As an indicator, closing below this level would act as the catalyst to exit a position. This has yet to occur. Year-to-date, this trend line had been tested on numerous occasions and every time, buyers continue to step up to support this uptrend line. It is difficult to dispute the significance of this trend line at this current juncture, and as long as SHOP stock remains above the uptrend line, I can only assume that higher prices will prevail.


Ebates Coupons and Cash Back

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )



Buz Investors Status Introduces CommitETH The development team behind Status, the leading mobile decentralized web browser for Ethereum, is pleased to introduce CommitETH,

Status Introduces CommitETH: A tool for enabling community driven development models

Extending GitHub to allow for incentivized contributions to open source projects

Buz Investors Status Introduces CommitETH The development team behind Status, the leading mobile decentralized web browser for Ethereum, is pleased to introduce CommitETH,

Buz Investors Status Introduces CommitETH The development team behind Status, the leading mobile decentralized web browser for Ethereum, is pleased to introduce CommitETH, a tool designed to foster open source software development. Our hope is that CommitETH will not only create stronger incentives for developers to get involved with open source projects, but also provide greater utility to app tokens, and provide token holders with direct say in the development direction of projects in the ecosystem.

As the web continues its shift towards decentralized business models powered by blockchains and protocol tokens, CommitETH will play a vital role in the evolution of their governance models and decision-making processes.



OTHER STORIES BUZ TRADERS FOLLOW

Status Introduces CommitETH

With CommitETH (https://commiteth.com/), holders of ETH, and soon ERC-20 tokens will be able to directly stake their holdings to drive the development of new features, the priority of bug fixes, and the implementation of integrations with other decentralized applications. This will have the impact of maximizing network effects and developer mindshare, expediting the rate of innovation and evolution across the Ethereum network as a whole.

At Status our mission is to make the decentralized web easy to access and interact with for all. The release of CommitETH marks the first step towards a decentralized organizational structure, by establishing a mechanism that will democratize our development, leading to a product created for the community by the community, something far more useful than we could build on our own.

The first release runs on the Ropsten Testnet, and developers and open source communities are encouraged to experiment and provide feedback.

Follow CommitETH

Homepage: https: https://commiteth.com/

Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




Corporate Update on Clinic Opening Status, New Patients and Observational Study

Canabo Medical Inc Update on Clinic Opening Status, New Patients and Observational Study

Corporate Update on Clinic Opening Status, New Patients and Observational Study

Corporate Update on Clinic Opening Status, New Patients and Observational Study

January 26, 2017 – Vancouver, British Columbia – Canabo Medical Inc. (TSX-V: CMM) (“Canabo” or the “Company”) is pleased to provide a corporate update relating to new clinic status and integration of CMC training and processes with partner clinics, new patient totals for the first quarter of operations and to announce the co-author team for its 2017 observational study.

Clinic Opening Status
In the first quarter of operations, Canabo has opened 2 new clinics in Kingston, Ontario; and Moncton, New Brunswick.  Clinic operations for both clinics began in January and the patient load has been strong. Over the next several weeks, Canabo expects to open additional clinics expanding into additional provinces within its emerging national network.  Training and systems integration activities are underway as planned with partner clinic operations in Alberta and Ontario. Clinic operations and new patient consultations are expected to begin in February.



Other Stories Bus Traders Follow

Canabo Medical Inc

 

New Patients
In the first quarter of operations, the Company is pleased to announce that it expects to add an additional 2,600 new patients to its patient load. Canabo maintains an extensive database of patient medical conditions, treatments, and patient reported efficacy.  In recent months, the company has been adding an average of 1,000 new patients per month, with some anticipated reduction in December due to holiday scheduling.

Neil Smith, Canabo Executive Chairman states, “New patient growth is now expected to exceed 1,000 new patients each month given the Company’s new stand alone and partner clinic practices.  This is an important targeted milestone met. Training and on-boarding is well under way and we expect to see increased patient flow in the next Quarter.”

Observational Study
Canabo expects to publish the first research report from its Observations Study this spring (see news release dated December 7, 2016).  Today, the Company is pleased to be providing an update on study parameters and the co-authored medical team.

Canabo is collecting data on how cannabis might interact with or lessen the need for pharmaceutical treatments. Preliminary research has indicated that benzodiazepine use may be falling among Canabo patients. The Company currently tracks over 1500 patients who started medical cannabinoids while on benzodiazepines.

The Company is also collecting data as to what extent cannabis serves as a substitute or effective complement to traditional opioid therapies. The Company is currently tracking over 3500 patients who are taking opioids for a large variety of pain and other disorders.  Roughly 55% of the company’s patient base consists of long-term pain patients.

Danial Schecter, Canabo’s Chief Medical Officer states, “Canabo has the nation’s largest and most extensive medical database for tracking cannabinoid treatments.  Our database will play a significant role in improving medical knowledge on how cannabis can support a variety of conditions and change how physicians prescribe other traditional more expensive treatment regimes”.

The Company expects to publish peer-reviewed papers on benzodiazepine-cannabinoid relationships this spring, and opioid-cannabinoid relationship later in 2017.  The study co-author team currently includes;

Andrew Davis, PhD

Dr. Andrew Davis received his Ph.D. and M.A. in Economics from the University of Rochester, where he also held both a Sproull Fellowship and a Lionel McKenzie Fellowship, and a B.Sc. from Memorial University of Newfoundland. Dr. Davis has regularly presented research at a variety of seminars and conferences including the Canadian Economics Association, of which he is a member, and is most recently published in Economic Modelling.

Danial Schecter, MD, CCFP

Dr. Schecter is co-founder of the Cannabinoid Medical Clinic (CMClinic) and a practicing family physician. As a recognized medical expert in the field of prescription cannabinoids and medical marijuana, Dr. Schecter has given numerous presentations to fellow physicians and developed educational programs on this subject.

Michael Verbora, MBA, MD, CCFP

Dr. Michael Verbora earned his medical degree at the University of Western Ontario and his Master of Business Administration (MBA) from the Odette School of Business. To date Dr. Verbora has completed over two thousand initial consultations for cannabinoid therapy. He has also presented for the Ontario College of Family Physicians annual Windsor pain conference on cannabinoid therapy. Dr. Verbora is a member of the Canadian Consortium for the Investigation of Cannabinoids (CCIC), Doctors for Responsible Access (DRA) and the Canadian Pain Society (CPS).

Mark Taylor, MD, FRCS(C), FACS

Dr. Mark Taylor is currently a Professor as well as the Interim Head of the Division of Otolaryngology-Head and Neck Surgery at Dalhousie University. Dr. Taylor has 15 years’ experience as a Head and Neck Surgeon in Halifax in addition to resident education. His practice focuses on Head and Neck Oncology, as well as Facial Plastic and Reconstructive Surgery, in which he is also Board Certified. Dr. Taylor has over 150 peer reviewed publications to his credit and has a particular interest in research into cannabinoid therapy.

Gwyllyn Goddard, BSc, MD, CCFP

Dr. Goddard is a family practitioner with a Bachelor of Science in microbiology/immunology and a doctorate in medicine from the University of Saskatchewan.  He has special interests in chronic disease prevention and management, the clinical use of cannabinoids and significant experience in working overseas in disaster and third-world medicine scenarios. He currently practices in British Columbia and has 9 years of clinical experience authorizing medical cannabis under the MMAR, MMPR and ACMPR Health Canada programs.

About the Company

Canabo Medical Inc. is a Canadian corporation incorporated on March 19, 2014. Canabo wholly owns and operates Cannabinoid Medical Clinics, Canada’s largest referral-only clinics for medical cannabis. After opening in 2014, Canabo now has twelve clinic locations, including Toronto, Barrie, Ottawa, Hamilton, Halifax, St. John’s, Calgary, Kingston, Moncton and Edmonton, with a number of additional clinics planned for opening in 2017.

The principal business carried on and intended to be carried on by Canabo is the operation of strictly referral-only medical clinics for evaluating the suitability of, prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress. Canabo sees patients only on a physician-referral basis. The Access to Cannabis for Medical Purposes Regulations (“ACMPR”) requires that medical marijuana must be prescribed by a health care practitioner; however, no cannabinoid products or medical marijuana are sold at Canabo’s cannabinoid medical clinics.

Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )